“…This included clinical signs and symptoms used to screen for PAH in other populations (eg, fatigue, dyspnea, palpitations and arrhythmia, volume retention, ECG changes), which are often noted in ACHD. 21 , 29 , 30 , 31 , 32 , 33 , 34 , 35 No clinically meaningful associations between patient characteristics and clinical course or rate of newly-diagnosed PAH were identified from ACHD-QuERI data. We are cautious not to overextend this conclusion, as valid quantification of newly diagnosed PAH requires hemodynamic assessment via RHC, which was performed in a minority of patients.…”